Rocket Pharmaceuticals Inc (RCKT) concluded trading on Wednesday at a closing price of $3.2, with 4.33 million shares of worth about $13.86 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -74.52% during that period and on July 09, 2025 the price saw a gain of about 8.11%. Currently the company’s common shares owned by public are about 106.75M shares, out of which, 99.77M shares are available for trading.
Stock saw a price change of 23.55% in past 5 days and over the past one month there was a price change of 4.40%. Year-to-date (YTD), RCKT shares are showing a performance of -83.97% which decreased to -74.54% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.19 but also hit the highest price of $26.98 during that period. The average intraday trading volume for Rocket Pharmaceuticals Inc shares is 5.08 million. The stock is currently trading 13.72% above its 20-day simple moving average (SMA20), while that difference is down -27.98% for SMA50 and it goes to -68.63% lower than SMA200.
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) currently have 106.75M outstanding shares and institutions hold larger chunk of about 86.58% of that.
The stock has a current market capitalization of $344.76M and its 3Y-monthly beta is at 0.61. It has posted earnings per share of -$2.63 in the same period. It has Quick Ratio of 9.19 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RCKT, volatility over the week remained 7.56% while standing at 8.18% over the month.
Analysts are in expectations that Rocket Pharmaceuticals Inc (RCKT) stock would likely to be making an EPS of -0.53 in the current quarter, while forecast for next quarter EPS is -0.51 and it is -1.49 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.6 which is -0.15 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.74 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 18.96% while it is estimated to increase by 27.63% in next year. EPS is likely to grow at an annualized rate of 21.48% for next 5-years, compared to annual growth of -11.60% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Evercore ISI on May 30, 2025 offering an In-line rating for the stock and assigned a target price of $5 to it. Coverage by Morgan Stanley stated Rocket Pharmaceuticals Inc (RCKT) stock as an Equal-weight in their note to investors on May 28, 2025, suggesting a price target of $7 for the stock. Stock get a Hold rating from Jefferies on May 28, 2025.
